MOBERG DERMA HAS COMPLETED RECRUITMENT FOR MOB-015 PHASE II CLINICAL STUDY

MOBERG DERMA HAS COMPLETED RECRUITMENT FOR MOB-015 PHASE II CLINICAL
STUDY

Moberg Derma AB (OMX: MOB) has successfully completed the recruitment of
237 patients with nail fungus (onychomycosis) to participate in the
ongoing MOB-015 phase II study. MOB-015 is the company's
second-generation topical treatment for nail fungus.

The purpose of the study, which includes 237 patients, is to confirm the
validity of the MOB-015 product concept and to provide the basis for a
phase III program as well as licensing. Patients will be followed-up
during 12 months and the endpoints normally accepted by FDA, EMA and
other relevant authorities for nail fungus are used.

“We are very pleased that patient recruitment has been successfully
completed and that the study is proceeding according to plan. MOB-015
has the potential to be the future market leader for the treatment of
nail fungus,” said Peter Wolpert, CEO of Moberg Derma.

About MOB-015 and nail fungus
MOB-015 is a new topical treatment for nail fungus (onychomycosis) with
fungicidal, keratolytic and emollient properties. Moberg Dermas
patent-pending formulation technology facilitates high concentrations of
a fungicidal substance to be transported in and through nail tissue. In
pre-clinical studies on human nails, more than tenfold concentrations of
the antifungal substance have been detected, compared to the
concentrations measured in the nail with successful oral treatment. As
MOB-015 is applied locally, the side effects associated with oral
treatment are avoided.

Nail fungus is the most common nail disease and afflicts approximately
10% of the general population and increasing with age. The estimated
global market potential exceeds USD 1 billion. The untapped potential is
significant since many patients remain untreated. It is generally
recognized that there is a need for new efficacious and safe topical
treatments.

For further information, please contact:
Peter Wolpert, President and CEO of Moberg Derma
Telephone: +46 8 522 307 00
Mobile: +46 70- 735 71 35
E-mail: peter.wolpert@mobergderma.se (peter.wolpert@mobergderma.se)

Magnus Persson, IR
Mobile: +46 73-355 26 01
E-mail: magnus.persson@mobergderma.se (magnus.persson@mobergderma.se)